Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke - Full Text View

Purpose

This study will determine if NXY-059 will improve recovery from an acute stroke. The study is designed to look at both overall recovery and recovery of motor function, for example muscle strengthen and coordination.

Condition	Intervention	Phase
Cerebral Stroke Stroke, Acute Cerebrovascular Stroke Ischemic Attack, Transient	Drug: NXY-059	Phase II Phase III

MedlinePlus related topics:

Transient Ischemic Attack

Drug Information available for:

Disufenton sodium

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Factorial Assignment, Safety/Efficacy Study

Official Title:	SAINT (Stroke - Acute Ischemic - NXY Treatment) A Double Blind, Randomized, Placebo Controlled, Parallel Group, Multicenter, Phase IIb/III Study to Assess the Efficacy and Safety of Intravenous NXY-059 in Acute Ischemic Stroke

Further study details as provided by AstraZeneca:

Primary Outcome Measures:

Global disability on modified Rankin scale at 90 days.

Secondary Outcome Measures:

NIH stroke scale
Barthel Index
Stroke Impact Scale
EQ-5D all at 90 days
Safety outcomes

Estimated Enrollment:	3200
Study Start Date:	May 2003

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Males and females
Acute ischemic stroke with limb weakness
Onset of symptoms within 6 hours
Full functional independence prior to the present stroke

Exclusion Criteria:

Unconsciousness
Subjects who are unlikely to complete the infusion of investigational product and/or are unlikely to undergo active medical management during that period due to a severe clinical condition.
Severe illness with life expectancy less than 6 months.
Known severe kidney disorder.
Current known alcohol or illicit drug abuse or dependence.
Pregnant or breast-feeding.
Treatment with acetazolamide and methotrexate is not permitted during the infusion
Participation in a previous clinical study within 30 days.
Meets all other exclusion criteria.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00061022

Show 258 Study Locations

Sponsors and Collaborators

AstraZeneca

Investigators


Study Director:	AstraZeneca NXY-059 Medical Science Director, MD	AstraZeneca

More Information

Publications indexed to this study:

Shuaib A, Lees KR, Lyden P, Grotta J, Davalos A, Davis SM, Diener HC, Ashwood T, Wasiewski WW, Emeribe U; SAINT II Trial Investigators. NXY-059 for the treatment of acute ischemic stroke. N Engl J Med. 2007 Aug 9;357(6):562-71.

Study ID Numbers:	SA-NXY-0007, 007, SAINT 2
First Received:	May 20, 2003
Last Updated:	November 1, 2006
ClinicalTrials.gov Identifier:	NCT00061022
Health Authority:	United States: Food and Drug Administration

Keywords provided by AstraZeneca:

Stroke

cerebral vascular accident

CVA

Ischemia

Hemorrhage

TIA

Transient Ischemic Attack

Brain Attack

Cataplexy

Study placed in the following topic categories:

Ischemic Attack, Transient

Cerebral Infarction

Stroke

Vascular Diseases

Disufenton sodium

Central Nervous System Diseases

Ischemia

Hemorrhage

Brain Diseases

Cerebrovascular Disorders

Cataplexy

Brain Ischemia

Brain Infarction

Infarction

Additional relevant MeSH terms:

Antioxidants

Pathologic Processes

Molecular Mechanisms of Pharmacological Action

Therapeutic Uses

Physiological Effects of Drugs

Nervous System Diseases

Cardiovascular Diseases

Cardiovascular Agents

Protective Agents

Pharmacologic Actions

ClinicalTrials.gov processed this record on November 20, 2008

Sponsored by:	AstraZeneca
Information provided by:	AstraZeneca
ClinicalTrials.gov Identifier:	NCT00061022